List of Tables
- Table 1-01. CDC travel notice defiitions
- Table 2-01. Revaccination (booster) schedules
- Table 2-02. Recommended intervals between administration of antibody-containing products and measles-containing vaccine or varicella-containing vaccine
- Table 2-03. Recommended and minimum ages and intervals between vaccine doses
- Table 2-04. Vaccines described in the CDC Yellow Book and recommendations by ACIP
- Table 2-05. Composition of the World Health Organization oral rehydration salts for diarrheal illness
- Table 2-06. Risk categories for acute mountain sickness
- Table 2-07. Recommended medication doses to prevent and treat altitude illness
- Table 2-08. Medications that may increase nausea
- Table 2-09. Comparison of water disinfection techniques
- Table 2-10. Microorganism size and susceptibility to filtration
- Table 2-11. Countries with the highest estimated traffic death rates
- Table 2-12. Estimated traffic death rates in the 20 countries most frequently traveled by US residents
- Table 2-13. Recommended strategies to reduce injuries while traveling internationally
- Table 3-01. Countries with endemic diphtheria
- Table 3-02. Licensed doses and schedules for Havrix
- Table 3-03. Licensed doses and schedules for Vaqta
- Table 3-04. Licensed doses and schedules for Twinrix
- Table 3-05. Recommended doses of immune globulin (IG) to protect against hepatitis A
- Table 3-06. Interpretation of serologic test results for hepatitis B virus infection
- Table 3-07. Administration of human papillomavirus (HPV) vaccines
- Table 3-08. Risk for Japanese encephalitis, by country
- Table 3-09. Reliable supply regimens for the treatment of malaria
- Table 3-10. Considerations when choosing a drug for malaria prophylaxis
- Table 3-11. Drugs used in the prophylaxis of malaria
- Table 3-12. Changing medications as a result of side effects during chemoprophylaxis
- Table 3-13. Countries and political units that reported no indigenous cases of rabies during 2009
- Table 3-14. Criteria for preexposure immunization for rabies
- Table 3-15. Preexposure immunization for rabies
- Table 3-16. Postexposure immunization for rabies
- Table 3-17. Classification, primary vector, and reservoir occurrence of rickettsiae known to cause disease in humans
- Table 3-18. Summary guide to tetanus prophylaxis in routine wound management
- Table 3-19. Tickborne encephalitis vaccination schedules
- Table 3-20. Dosage and schedule for typhoid fever vaccination
- Table 3-21. Countries with risk of yellow fever virus (YFV) transmission
- Table 3-22. Countries with low potential for exposure to yellow fever virus (YFV)
- Table 3-23. Contraindications and precautions to yellow fever vaccine administration
- Table 3-24. Countries that require proof of yellow fever vaccination from all arriving travelers
- Table 3-25. Categories of recommendations for yellow fever vaccination
- Table 5-01. Incubation periods of frequent febrile syndromes in returned travelers
- Table 5-02. Common causes of fever, by geographic area
- Table 5-03. Common infections, by incubation periods
- Table 5-04. Common clinical findings and associated infections
- Table 5-05. Treatment of common intestinal protozoan parasites
- Table 5-06. Skin lesions in returned travelers, by cause
- Table 7-01. Assessment of dehydration in infants
- Table 7-02. Recommended immunization schedule for ages 0–6 years—United States, 2011
- Table 7-03. Recommended immunization schedule for ages 7–18 years—United States, 2011
- Table 7-04. Recommended childhood catch-up immunization schedule—United States, 2011. Children and adolescents who start late or who are more than 1 month behind.
- Table 8-01. Immunization of immunocompromised adults
- Table 8-02. Potential interactions between malaria drugs and HIV drugs
- Table 8-03. Potential interactions between antibiotics for travelers’ diarrhea and HIV drugs
- Table 8-04. Special considerations for travelers with chronic medical illnesses
- Table 8-05. Potential contraindications to international travel during pregnancy
- Table 8-06. Greatest risks for pregnant travelers
- Table 8-07. Half-lives of selected antimalarial drugs
- Table 8-08. Vaccination during pregnancy
- Table 8-09. Diseases for which VFR travelers are at increased risk, proposed reasons for risk variance, and recommendations to reduce risks specific to travelers visiting friends and relatives
- Table 8-10. Differences between military populations and civilian traveling populations
- Table 8-11. Differences between CDC recommendations and US military’s use of malaria chemoprophylaxis
- Table 8-12. US study-abroad students, percentage by host region
- Table 9-01. Testing for required overseas medical screening examination
- Table B-01. Selected websites for the travel medicine practitioner
- Table B-02. Selected travel medicine resources providing RSS feeds
- Table C-01. Travel vaccine summary
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - Contact CDC-INFO